Imbalance of the Humoral Component of the Immune System as a Basis for the Progression of Non-Alcoholic Fatty Liver Disease in Patients with Obesity and Concomitant Biliary Tract Pathology by Filippova, Aleksandra
Archive of Clinical Medicine 2016
Vol. 22, Issue 2, E201629
DOI: 10.21802/acm.2016.2.9
Research Article
Imbalance of the Humoral Component of the
Immune System as a Basis for the Progression of
Non-Alcoholic Fatty Liver Disease in Patients with
Obesity and Concomitant Biliary Tract Pathology
Aleksandra Filippova
Abstract
The objective of the research was to study the features of the indicators of the humoral component of the immune system
depending on the body mass index in patients with non-alcoholic hepatic steatosis, non-alcoholic steatohepatitis, concomitant
obesity and biliary tract pathology.
Material and methods. 200 patients with non-alcoholic fatty liver disease, concomitant obesity and biliary tract pathology
including 100 patients with non-alcoholic hepatic steatosis and 100 with non-alcoholic steatohepatitis were examined. 70 out
of 100 patients with non-alcoholic steatohepatitis had the minimum level of alanine transaminase activity and 30 patients
had a moderate alanine transaminase activity. The control group included 30 apparently healthy persons. The body mass
index was determined using the Quetelet formula. All the patients with non-alcoholic hepatic steatosis and non-alcoholic
steatohepatitis were divided into three groups depending on the increase in the body mass index and the presence of biliary
tract pathology. The humoral immune system state was evaluated by the levels of immunoglobulins A, M and G and the
content of circulating immune complexes.
Results. In patients with non-alcoholic hepatic steatosis and non-alcoholic steatohepatitis, concomitant obesity and biliary
tract pathology, there were observed abnormalities in the humoral component of the immune system with possible increase
in the levels of major immunoglobulin classes as well as in the content of circulating immune complexes being more
pronounced in patients with non-alcoholic steatohepatitis compared to patients with non-alcoholic hepatic steatosis (p<0.05)
and apparently healthy persons (p<0.001). The increase in the body mass index led to a significant increase in the levels of
Ig A, M, G and the activation of circulating immune complexes.More significant changes in humoral indices were observed
in patients with chronic non-calculous and calculous cholecystitis in the presence of inflammatory biliary tract changes
during the exacerbation of the pathology compared to patients who underwent cholecystectomy on the background of the
aggravation of postcholecystectomy syndrome.
Conclusions. The obtained data indicated that one of the elements in the pathogenesis of non-alcoholic fatty liver disease
with concomitant obesity and biliary tract pathology is a significant change in the indicators of humoral immunity, namely the
increase in the levels of Ig (A, M, G) and circulating immune complexes which depend on the clinical form (non-alcoholic
hepatic steatosis or non-alcoholic steatohepatitis), increase in the body mass index and the presence of biliary tract
comorbidity.
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1. Problem statement and analysis of the
recent research
In recent years, the role of the liver as one of the major organs
of the immune system has been widely recognized due to the
population of macrophages and killer cells it contains. They
are components of the innate immune system [1, 4, 6]. How-
ever, the humoral immune response in case of non-alcoholic
fatty liver disease (NAFLD) with concomitant obesity (OB)
and biliary tract (BT) pathology is insufficiently studied; in the
literature there some data about changes in the liver innate im-
munity and the role of acquired immunity in the progression
of NAFLD [5].
In NAFLD, the process of disease progression is of great
importance. Recurrent, and in some cases continuous exac-
erbations are caused by both humoral [7] and cellular [8]
immune disorders. Therefore, the study of the causes and
progression mechanisms of fatty liver disease from the per-
spective of immunology is one of the relevant problems. The
understanding of the disorders of immunological reactivity,
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which determine the pathological process activity has both
diagnostic and prognostic value.
The study of the humoral component of the immune sys-
tem in patients at different stages of NAFLD has not been
conducted and the mechanisms responsible for the develop-
ment and progression of NAFLD with concomitant OB and
BT pathology are not fully understood. There is a need in
more detailed study of changes in the humoral immune sys-
tem caused by immunoregulatory disorders and concomitant
NAFLD to improve the efficiency of diagnosing the disease.
The objective of the research was to study the features
of the indicators of the humoral component of the immune
system depending on the body mass index (BMI) in patients
with non-alcoholic hepatic steatosis (NASP), non-alcoholic
steatohepatitis (NASH), concomitant OB and BT pathology.
2. Materials and methods
There were examined 200 patients with NAFLD, concomitant
OB and BT pathology, who were hospitalized to the clinic
of the Institute of Gastroenterology of NAMS of Ukraine
(100 patients with NAHS and 100 patients with NASH). Dur-
ing sonographic or morphological examination of the liver
bioptate, the signs of hepatic steatosis were detected, includ-
ing 100 patients with NAHS and 100 with NASH. 70 out of
100 patients with NASH had the minimum level of alanine
transaminase activity (min. a.) and 30 patients had a moderate
activity (mod. a.) of alanine transaminase. There were 59
(29.5%) males and 141 (70.5%) females. The average age
was (52.57±0.79) years. The control group consisted of 30
apparently healthy persons (AHP), compared by age (the av-
erage age – 49.4±2.52 years) and sex (8 males – 26.7%, 22
females – 73.3%) with patients of the main groups (p>0.05).
The diagnosis of NAFLD, OB and BT pathology was
made according to standardized protocols for diagnosis and
treatment of digestive diseases in accordance with the Order
of the Ministry of Health of Ukraine of 13.06.2005 No 271
[2], standardized clinical protocols for primary, secondary
(specialized) medical care “Non-alcoholic steatohepatitis” [3],
ICD-10 and WHO criteria, as well as the World Gastroenterol-
ogy Organization Global Guidelines (WGO Global Guideline
Obesity) [10], on the basis of the patient’s medical history,
clinical and instrumental (abdominal ultrasound, intraopera-
tive liver biopsy) examinations with the obligatory consider-
ation of the biochemical parameters and the increase in the
level of liver enzymes. The patients included in the study, did
not abuse alcohol (consumption <50 g of ethanol/week by
males and <30 g of ethanol/ week by females during the past
year). There were detected no serum markers of viral hepatitis
B and C, autoimmune and hereditary liver diseases.
All the patients underwent anthropometric examination:
they were weighted on an empty stomach, their height was
measured, waist circumference (WC) and hip circumference
(HC) were determined. The index of waist-to-hip ratio (WHR)
was used to determine the type of body fat distribution. Women
with the value of WHR >0.88 and men with the value of WHR
>0.90 were considered as those having abdominal obesity
[10]. The BMI was determined using the Quetelet formula.
Depending on the decrease in the BMI, all the patients with
OB and NAHS or NASH were divided into six groups: the
BMI of 25–29.9 kg/m2 – excessive body mass (Group 1 and
Group 4); the BMI of 30–34.9 kg/m2 – first-degree obesity
(Group 2 and Group 5); the BMI of 35–39.9 kg/m2 – second-
degree obesity (Group 3 and Group 6). Depending on the pres-
ence of BT comorbidity, each group of patients with NAHS
and OB or NASH with OB was divided into three subgroups:
chronic non-calculous cholecystitis (CNC) – subgroups 1a
and 2a, chronic calculous cholecystitis (CCC) – subgroups 1b
and 2b, concomitant postcholecystectomy syndrome (PCS) –
subgroups 1c and 2c.
The status of the humoral immune system was evaluated
by the levels of immunoglobulins A, M and G and the content
of circulating immune complexes (CIC). Changes in the levels
of immunoglobulins A, M, G in blood serum were determined
using radial immunodiffusion (Mancini technique – 1965)
[9]. CIC was determined using the method proposed by V.
Haskova (1977) [11].
Licensed program STATISTICA 6.1 (No AGAR909E4158-
22FA) was used for statistical analysis. The hypothesis of
normal distribution of quantitative data was tested by the
Kolmogorov-Smirnov test. The qualitative indices are given
as the mean value and the standard error of the mean (M±m).
For comparison of mean values in all subgroups the Student’s
t-test was used considering homo- or heteroscedasticity of
variances (the Fisher’s exact test) and univariate disperse anal-
ysis ANOVA; for comparison of relative indices the Pearson’s
chi-squared test (χ2) was used. To assess the relationship be-
tween signs the correlation analysis with the calculation of the
Spearman’s rank correlation coefficient (rs) was performed.
3. Results and Discussion
The immunological examination of the humoral component
of the immune system showed that patients with NAFLD
and concomitant OB on the background of BT pathology
had almost similar changes in the immunological parameters
which depended on the presence of NAHS or NASH (Table
1). These changes in the humoral component of the immune
system increased with the progression of NAFLD from NAHS
to NASH (according to ANOVA from pF<0.05 to pF<0.001).
The important indicator of humoral immunity is the con-
tent of the immunoglobulins (Ig) A, M and G in blood serum,
which reflects the equilibrium between their synthesis and
breakdown. Many bacterial products, endotoxins which are
formed in hepatobiliary pathology enter the blood circulation
as circulating antigens being able to activate the system of
humoral immunity [1, 8].
According to the data presented in Table 1, an increased
number of A, M, G immunoglobulins was observed in all ex-
amined groups. The indicators of IgA in patients with NAHS
were 2.70±0.11 g/l and increased by 1.6 times compared to
the level of AHP being 1.73±0.20 g/l, while in patients with
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Table 1. Indices of humoral immunity in patients with non-alcoholic fatty liver disease, concomitant obesity and biliary tract
pathology (M±m)




IgA, g/l 1.73±0.20 2.70±0.11** 3.16±0.12**’ 3.46±0.23**” <0.001
IgM, g/l 1.56±0.12 1.79±0.06* 2.10±0.07**’ 2.52±0.15**#” <0.001
IgG, g/l 13.03±0.47 15.05±0.54* 17.54±0.61**’ 19.82±0.53**#” <0.001
CIC, optical density units 3.33±0,27 5.39±0.27** 6.13±0.37**’ 7.03±0.66**’ 0.024
Note.
* – p<0.05; ** – p<0.001 compared to AHP;
# – p<0.05 compared to the group of patients with NASH and min. a.;
’ – p<0.05; ” – p<0.001 compared to the group of patients with NAHS;
pF – level of significance of difference in the indices between groups with NAFLD in total according to univariate disperse analysis ANOVA
NASH and min. a. and patients with NASH and mod. a. their
level reached 3.16±0.12 g/l and 3.46±0.23 g/l increasing
from 1.8 to 2.0 times respectively (p<0.001 for all compar-
isons). Intergroup comparison showed that the highest IgA
levels were detected in patients with NASH and min. a. and
patients with NASH and mod. a. with the increase from 1.2
to 1.3 times compared to patients with NAHS (p<0.05 and
p<0.001).
The indicators of IgM increased in all observation groups
with a minimum increase by 1.15 times in patients with NAHS
being 1.79±0.06 g/l compared to 1.56 ±0.12 g/l in AHP
(p<0.05). The maximum level of IgM– 2.52±0.15 g/l was
observed in patients with NASH and mod. a. with an increase
by 1.6 times as related to AHP (p<0.001), by 1.2 times as
related to patients with NASH and min. a. (p<0.05) and by
1.4 times compared to patients with NAHS (p<0.001).
The study of IgG levels demonstrated the increase in this
index in all groups of the observation with a tendency to the
maximum parameters in patients with NASH and mod. a.
The minimal elevation in IgG was observed in patients with
NAHS: only by 1.15 times as related to AHP (p<0.05), while
patients with NASH and min. a. and patients with NASH and
mod. a. had the increase by 1.3 and 1.5 times, respectively
(p<0.001). The maximum level of the indicator was observed
in patients with NASH and mod. a. (19.82±0.53 g/l) with
an increase by 1.3 times compared to patients with NAHS
(p<0.001) and 1.13 times compared to patients with NASH
and min. a. (p<0.05).
An important function of immunoglobulins is the neu-
tralization of the antigens with the formation of CIC and
their subsequent elimination from the body, which is aimed
at maintaining the immunological balance [1]. We consid-
ered it appropriate to determine the content of CIC in the
blood serum as an important component in the pathogenesis
of immune destruction in case of concomitant NAFLD.
CIC is a physiological product of the antigen-antibody
reaction, which is the part of the protective immune mech-
anisms. The formation of immune complexes is an integral
indicator of developing the humoral immune response [1]. A
certain level of immune complexes must be constantly present
in the blood for the implementation of physiological processes
maintaining homeostasis. Moreover, it indicates an adequate
reaction of the organism to external influence [5]. However, it
should be noted that in case of excessive accumulation of CIC
due to their increased production or insufficient removal from
the body, a transition toward the pathology may occur, which
is caused by the increase in biological activity of immune
complexes which under special conditions play an undeni-
able role in the pathogenesis of autoimmune processes [8].
In patients with NAHS, the level of CIC increased by 1.6
times comparing to AHP while in patients with NASH and
min. a. and patients with NASH and mod. a., it increased by
1.8 and 2.1 times, respectively (p<0.001 for all comparisons).
Intergroup comparison showed that the highest values of CIC
were observed in patients with NASH and min. a. (6.13±0.37
optical density units) and patients with NASH and mod. a.
(7.03±0.66 optical density units) exceeding those in patients
with NAHS (5.39±0.27 optical density units) by 1.14 and
1.3 times, respectively (p<0.05 for all comparisons). The
increase in serum levels of CIC in patients with NAFLD, con-
comitant OB and BT pathology was probably associated with
the increase in the intensity of their formation and impaired
mechanisms of their elimination.
The analysis showed that patients with NAHS and NASH
with concomitant OB and BT pathology had the disorders
of humoral immunity manifested themselves as a significant
increase in the levels of the main immunoglobulins (A, M,
G) and CIC content being associated with the increase in the
intensity of their formation and impaired mechanisms of their
elimination. They were more pronounced in patients with
NASH and min. a. and patients with NASH and mod. a. com-
pared to patients with NAHS (p<0.05) and AHP (p<0.001).
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The results of the correlation analysis confirmed the afore-
mentioned trends concerning different clinical forms of NAFLD,
namely NAHS and NASH. They led to different degrees of the
increase in the level of IgA (rs=0.423, p<0.001 and rs=0.522,
p<0.001), IgM (rs=0.184, p<0.05 and rs=0.395, p<0.001),
IgG (rs=0.174, p<0.05 and rs=0.514, p<0.001) and CIC
(rs=0.375, p<0.001, and rs=0.493, p<0.001) compared to
AHP.
The comparison of humoral immunity indicators in pa-
tients with NAFLD, concomitant OB and BT pathology de-
pending on the BMI allowed ascertaining the fact that the
increase in body weight leads to significant changes in Ig A,
M, G, and CIC (Table 2). In Group 1, IgA level increased
by 1.3 times only being 2.33±0.18 g/l, compared to AHP -
1.73±0.20 g/l (p<0.05). In Group 2 and Goup 3, the increase
in IgA was more significant. The indicators were equal to
2.53±0.15 g/l and 3.30±0.20 g/l, i.e. by 1.5 and 1.9 times
higher than the data of AHP (p<0.001). The maximum value
of IgA was observed in Group 3 with a probable difference
by 1.3 and 1.4 times compared to patients of Group 2 and
patients of Group 1 (p<0.05 and p<0.001).
Intergroup analysis showed that the highest IgM levels
were observed in patients of Group 3 being 2.05±0.10 g/l with
an increase by 1.3 times compared to AHP (p<0.001) and
patients of Group 1 (p<0.001) and by 1.15 times compared to
Group 2 (p<0.05; pF=0.002).
The maximum value of IgG was observed in patients
of Group 3 being 17.61±0.95 g/l with an increase by 1.4
times compared to 13.03±0.47 g/l in AHP (p<0.001) and
13.0±0.90 g/l in patients of Group 1 (p<0.001); with an
increase by 1.2 times compared to Group 2 –14.63±0.83 g/l
(p<0.05; pF=0.002).
There was detected a significant increase in CIC in patients
of Group 2 and Group 3: 5.80±0.51 optical density units and
6.17±0.39 optical density units with an increase by 1.7 and
1.9 times, respectively compared to AHP with CIC level of
3.33±0.27 optical density units (p<0.001) and increase by
1.4 and 1.5 times, respectively compared to Group 1 with the
level of immune complexes of 4.11±0.37 optical density units
(p<0.05 and p<0.001).
Similar but more profound changes in humoral immunity
were observed in patients with NASH (Table 2). Group indi-
cators of IgA increased compared to AHP in all groups – from
1.7 times in Group 4 to 2.2 times in Group 6 (p<0.001 for
all comparisons). The highest level of IgA was observed in
Group 6 being 3.81±0.25 g/l with an increase by 1.3 and 1.2
times compared to patients of Group 4 and Group 5 (p<0.05
for all comparisons; pF=0.013).
IgM indicators in all observed groups significantly ex-
ceeded those in AHP (p<0.001). The maximum group in-
crease in IgM by 1.15 times was noted in Group 6; the level
of IgM was equal to 2.41±0.12 g/l versus 2.10±0.09 g/l in
patients of Group 4 (p<0.05).
Similar trends were observed when studying the concen-
tration of IgG in blood serum of patients with NASH: there
was detected a significant increase from 1.3 times in Group
4 to 1.6 times in Group 6 compared to AHP (p<0.001); the
maximum value of IgG was detected in Group 6 compared to
patients of Group 4 and Group 5 (p<0.05; pF=0.016).
The increase in CIC parameters in patients with NASH
were statistically significant compared to AHP as well. The
increase by1.7 times was detected in Group 4; by1.9 times
– in Group 5; by 2.3 times – in Group 6 (p<0.001 for all
comparisons). As in the previous cases, the highest values
of immune complexes were detected in patients of Group 6;
they increased by 1.3 times compared to patients of Group 4
(p<0.05).
Thus, the conducted research allowed us to detect the fea-
tures of the humoral responses in patients with NAHS and
NASH, concomitant OB and BT pathology, that were depen-
dent on the BMI parameters. The increase in the BMI was
found to be accompanied by more pronounced reaction of Ig
A, M, G and more significant activation of CIC. The obtained
data allowed us to assume a correlation relationship between
indicators of humoral immunity and the BMI parameters in
patients with comorbid NAFLD and OB on the background
of BT pathology. It was confirmed by the results of the cor-
relation analysis. In particular, in patients with NAHS and
NASH, an increase in the BMI resulted in elevated levels of
IgA (rs=0.323, p<0.001 and rs=0.20, p<0.05), IgM (rs=0.325,
p<0.001 and rs=0.189, p<0.05), IgG (rs=0.262, p<0.01 and
rs=0.191, p<0.05) and CIC (rs=0.321, p<0.001 and rs=0.223,
p<0.05), respectively.
Subsequently, we investigated the relationship between
the parameters of humoral immunity in patients with NAFL,
concomitant OB and BT comorbidity using the comparative
analysis (Table 3). Among patients with NAHS, the level
of IgA increased by 1.5 times in subgroup 1a (p<0.05) and
subgroup 1c (p<0.001) as related to AHP. The highest level
of IgA was observed in subgroup 1b. There was an increase
by 1.7 times as related to AHP (p<0.001).
The indicators of IgM and IgG in patients of subgroup
1a and subgroup 1b were statistically compared to the group
of AHP (p>0.05 for all comparisons). In case of CCC, the
levels of immunoglobulin M and G exceeded those in AHP
by 1.3 times (p<0.05 and p<0.001, respectively); in patients
of subgroup 1c, they exceeded the levels by 1.2 and 1.3 times
(p<0.05).
CIC indicators were the highest in subgroup 1a and sub-
group 1b with an increase by 1.8 and 1.7 times compared
to AHP (p<0.001). Intergroup comparison showed that the
lowest intergroup level of immune complexes was observed
in subgroup 1c being higher than the normal one by 1.4 times
only (p<0.05) and significantly different from the values of
patients of subgroup 1b (p<0.05).
Similar but more significant changes were observed in
patients with NASH. Thus, in almost all groups of patients
with NASH, IgA levels increased approximately twofold com-
pared to AHP (p<0.001 for all comparisons). Almost simi-
lar increase in the indicators of IgM (from 1.4 to 1.5 times
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Table 2. Comparative characteristics of the indicators of humoral immunity in patients with non-alcoholic fatty liver disease,
concomitant obesity and biliary tract pathology depending on the body mass index (M±m)
Group CIC, optical
density units
IgA, g/l IgM, g/l IgG, g/l
AHP (n=30) 3.33±0.27 1.73±0.20 1.56±0.12 13.03±0.47
NAHS
Group 1, BMI -
25-29.9 kg/m2
(n=31)
4.11±0.37 2.33±0.18 * 1.54±0.11 13.0±0.90
Group 2, BMI -
30-34.9 kg/m2
(n=38)
5.80±0.51 **# 2.53±0.15 ** 1.79±0.09 # 14.63±0.83
Group 3, BMI -
35-39.9 kg/m2
(n=31)




0.004 <0.001 0.002 0.002
NASH
Group 4, BMI -
25-29.9 kg/m2
(n=40)
5.67±0.47 ** 3.02±0.13 ** 2.10±0.09 ** 17.29±0.88 **
Group 5, BMI -
30-34.9 kg/m2
(n=37)
6.42±0.53 ** 3.16±0.19 ** 2.25±0.12 ** 17.74±0.65 **
Group 6, BMI -
35-39.9 kg/m2
(n=23)
7.65±0.74 **# 3.81±0.25 **#’ 2.41±0.12 **# 20.62±0.64 **#’
pF between
groups
0.066 0.013 0.180 0.016
Note.
* – p<0.05; ** – p<0.001 compared to AHP;
# – p<0.05; ## – p<0.001 compared to the group of patients with the BMI of 25-29.9 kg/m2;
’ – p<0.05 compared to the group of patients with the BMI of 30-34.9 kg/m2;
pF – level of significance of difference in the indices between groups with different BMI in total according to univariate disperse analysis
ANOVA
compared to normal values) was found in all groups of the
observation (p<0.001 for all comparisons). The dependence
from BT comorbidity was observed when studying intergroup
indices of IgG. The highest level was seen in subgroup 2a
and subgroup 2b with an increase by 1.4 and 1.5 times com-
pared to AHP (p<0.001), while the lowest level was seen in
subgroup 2c with an increase by 1.3 times compared to AHP
(p<0.001) and by 1.2 times compared to patients of subgroup
2b (p<0.05).
Similar changes were observed when studying the indicators
of CIC. Thus, the highest intergroup level of immune com-
plexes was observed in subgroup 2a and subgroup 2b with
an increase by 2.1 times (p<0.001) and in subgroup 2c the
increase was by 1.6 times only compared to AHP (p<0.001)
and by 1.3 times as related to subgroup 2a and subgroup 2b
(p<0.05 for all comparisons).
The comparative intergroup analysis showed that the pres-
ence of BT comorbidity resulted in some changes in the im-
mune status of patients with comorbid NAFLD and OB. In
the presence of severe inflammatory BT changes during the
exacerbation of the pathology, more significant changes in hu-
moral indices were observed in patients with CNC and CCC
compared to patients who underwent cholecystectomy on the
background of PCS aggravation.
The aforementioned trends concerning the dependence of
the degree of changes in the parameters of humoral immunity
from concomitant BT pathology in patients with NAHS and
NASH were confirmed by the results of the correlation analy-
sis. Particularly, the presence of CNC or CCC in patients with
NAHS was found to lead to more increased levels of CIC,
immunoglobulin M and immunoglobulin G, rather than the
state after laparoscopic cholecystectomy: for CIC (rs=0.206,
p<0.05), for IgG (rs=0.221, p<0.05), for IgM (rs=0.201,
p<0.05). In patients with NASH: for CIC (rs=0.243, p<0.05),
for IgG (rs=0.218, p<0.05).
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Table 3. Comparative characteristics of humoral immunity indicators in patients with non-alcoholic fatty liver disease and
concomitant obesity depending on co-existent biliary tract pathology (M±m)
Group CIC, optical
density units
IgA, g/l IgM, g/l IgG, g/l




6.01±0.64** 2.57±0.21* 1.76±0.11 14.54±0.94
Subgroup 1b,
CCC (n=33)
5.53±0.31** 2.95±0.17** 2.0±0.09* 17.13±0.86**#
Subgroup 1c,
PCS (n=33)
4.61±0.32*’ 2.60±0.17** 1.63±0.10’ 13.47±0.92’
pF between
groups




6.95±0.64** 3.36±0.19** 2.35±0.12** 18.52±0.69**
Subgroup 2b,
CCC (n=30)
7.02±0.67** 3.33±0.19** 2.16±0.11** 19.49±0.69**
Subgroup 2c,
PCS (n=35)
5.32±0,31**#’ 3.08±0,17** 2.15±0,12** 16.84±0,94**’
pF between
groups
0.052 0.494 0.412 0.066
Note.
* – p<0.05; ** – p<0.001 compared to AHP;
# – p<0.05; ## – p<0.001 compared to the group of patients with CNC;
’ – p<0.05 compared to the group of patients with CCC;
pF – level of significance of difference in the indices between groups with different pathologies of the biliary tract in total according to
univariate disperse analysis ANOVA
4. Conclusions
Thus, the obtained data indicated that one of the elements in
the pathogenesis of NAFLD with concomitant OB and BT
pathology is a significant change in the indicators of humoral
immunity, namely the increase in the levels of Ig (A, M, G)
and CIC which depend on the clinical form (non-alcoholic
hepatic steatosis or non-alcoholic steatohepatitis), increase in
the BMI and the presence of BT comorbidity. Changes in the
indicators of humoral immunity shows the development of
immune deficiency in patients with comorbid NAFLD.
5. Prospects for further research
The study of the characteristics of T-cell immunity depending
on the body weight and BT pathology in patients with comor-
bid NAFLD, concomitant OB and BT pathology is promising.
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